Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases

Staging of brain pathology related to sporadic Parkinson’s disease

Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · see citing works

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378 · see citing works

Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

Biomarkers Definitions Working Group (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,771 · see citing works

Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics

Ong, S.-E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., Steen, H., Pandey, A., & Mann, M. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m200025-mcp200 · Cited by 5,574 · see citing works

Parkinson disease

Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415 · see citing works

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria

Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411 · see citing works

Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents

Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B., Parker, K., Hattan, S., Khainovski, N., Pillai, S., Dey, S., Daniels, S., et al. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m400129-mcp200 · Cited by 4,401 · see citing works

Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism

Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibáñez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,800 · see citing works

A Model for Random Sampling and Estimation of Relative Protein Abundance in Shotgun Proteomics

Liu, H., Sadygov, R. G., & Yates, J. R. (2004) · Analytical Chemistry · doi:10.1021/ac0498563 · Cited by 2,486 · see citing works

Tandem Mass Tags: A Novel Quantification Strategy for Comparative Analysis of Complex Protein Mixtures by MS/MS

Thompson, A., Schäfer, J., Kuhn, K., Kienle, S., Schwarz, J., Schmidt, G., Neumann, T., & Hamon, C. (2003) · Analytical Chemistry · doi:10.1021/ac0262560 · Cited by 2,386 · see citing works

Alzheimer's disease

Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336 · see citing works

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works

What are biomarkers?

Strimbu, K., & Tavel, J. A. (2010) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32833ed177 · Cited by 2,062 · see citing works

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049 · see citing works

Genome-wide association study reveals genetic risk underlying Parkinson's disease

Simón‐Sánchez, J., Schulte, C., Brás, J., Sharma, M., Gibbs, J. R., Berg, D., Paisán‐Ruiz, C., Lichtner, P., Scholz, S. W., Hernandez, D. G., et al. (2009) · Nature Genetics · doi:10.1038/ng.487 · Cited by 1,916 · see citing works

Protein biomarker discovery and validation: the long and uncertain path to clinical utility

Rifai, N., Gillette, M. A., & Carr, S. A. (2006) · Nature Biotechnology · doi:10.1038/nbt1235 · Cited by 1,867 · see citing works

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works

Alzheimer's disease

Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853 · see citing works

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · see citing works

High performance plasma amyloid-β biomarkers for Alzheimer's disease

Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681 · see citing works

The many faces of α-synuclein: from structure and toxicity to therapeutic target

Lashuel, H. A., Overk, C., Oueslati, A., & Masliah, E. (2012) · Nature reviews. Neuroscience · doi:10.1038/nrn3406 · Cited by 1,623 · see citing works

Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment

Jack, C. R., Petersen, R. C., Xu, Y. C., O’Brien, P. C., Smith, G. E., Ivnik, R. J., Boeve, B. F., Waring, S. C., Tangalos, E. G., & Kokmen, E. (1999) · Neurology · doi:10.1212/wnl.52.7.1397 · Cited by 1,404 · see citing works

α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models

Cooper, A. A., Gitler, A. D., Cashikar, A. G., Haynes, C. M., Hill, K. J., Bhullar, B., Liu, K., Xu, K., Strathearn, K. E., Liu, F., et al. (2006) · Science · doi:10.1126/science.1129462 · Cited by 1,377 · see citing works

Genetics of Parkinson's DiseasePreprint

Klein, C., & Westenberger, A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a008888 · Cited by 1,370 · see citing works

Selected reaction monitoring–based proteomics: workflows, potential, pitfalls and future directions

Picotti, P., & Aebersold, R. (2012) · Nature Methods · doi:10.1038/nmeth.2015 · Cited by 1,302 · see citing works

Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics

Peterson, A. C., Russell, J. D., Bailey, D. J., Westphall, M. S., & Coon, J. J. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o112.020131 · Cited by 1,288 · see citing works

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176 · see citing works

Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma

Addona, T. A., Abbatiello, S. E., Schilling, B., Skates, S. J., Mani, D. R., Bunk, D. M., Spiegelman, C. H., Zimmerman, L. J., Ham, A.-J. L., Keshishian, H., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1546 · Cited by 1,037 · see citing works

Clinical progression in Parkinson disease and the neurobiology of axons

Cheng, H., Ulane, C. M., & Burke, R. E. (2010) · Annals of Neurology · doi:10.1002/ana.21995 · Cited by 1,012 · see citing works

Accurate quantitation of protein expression and site-specific phosphorylation.

Oda, Y., Huang, K., Cross, F., Cowburn, D., & Chait, B. (1999) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.96.12.6591 · Cited by 1,011 · see citing works

The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception

Weiner, M. W., Veitch, D. P., Aisen, P. S. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Liu, E., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.1769 · Cited by 1,011 · see citing works

Hyperphosphorylation induces self-assembly of τ into tangles of paired helical filaments/straight filaments

Alonso, A. D. C., Zaidi, T., Novák, M., Grundke, I., & Iqbal, K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121119298 · Cited by 968 · see citing works

Biomarkers: Potential uses and limitations

Mayeux, R. P. (2004) · NeuroRx · doi:10.1602/neurorx.1.2.182 · Cited by 925 · see citing works

The diagnosis of Parkinson’s disease

Tolosa, E., Wenning, G., & Poewe, W. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70285-4 · Cited by 902 · see citing works

The many faces of tau

Morris, M., Maeda, S., Vossel, K., & Mucke, L. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.009 · Cited by 899 · see citing works

Cerebrospinal Fluid tau/β-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults

Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · see citing works

Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules

Alonso, A. D. C., Grundke-Iqbal, I., & Iqbal, K. (1996) · Nature Medicine · doi:10.1038/nm0796-783 · Cited by 859 · see citing works

Hydrogen exchange mass spectrometry for studying protein structure and dynamics

Konermann, L., Pan, J., & Liu, Y. (2010) · Chemical Society Reviews · doi:10.1039/c0cs00113a · Cited by 842 · see citing works

Next-generation proteomics: towards an integrative view of proteome dynamics

Altelaar, M. A. F., Muñoz, J., & Heck, A. J. R. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3356 · Cited by 776 · see citing works

Mass spectrometry for proteomics

Han, X., Aslanian, A., & Yates, J. R. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.07.024 · Cited by 743 · see citing works

PET imaging of amyloid deposition in patients with mild cognitive impairment

Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A. E., Ringheim, A., Långström, B., & Nordberg, A. K. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.029 · Cited by 725 · see citing works

Improved discrimination of AD patients using β-amyloid _(1-42) and tau levels in CSF

Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724 · see citing works

Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease

El‐Agnaf, O. M. A., Salem, S. A., Paleologou, K. E., Curran, M. D., Gibson, M. J., Court, J. A., Schlossmacher, M. G., & Allsop, D. (2006) · The FASEB Journal · doi:10.1096/fj.03-1449com · Cited by 715 · see citing works

Extracellular vesicles round off communication in the nervous system

Budnik, V., Ruiz-Cañada, C., & Wendler, F. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.29 · Cited by 712 · see citing works

Intraneuronal Alzheimer Aβ42 Accumulates in Multivesicular Bodies and Is Associated with Synaptic Pathology

Takahashi, R. H., Milner, T. A., Li, F., Nam, E. E., Edgar, M. A., Yamaguchi, H., Beal, M. F., Xu, H., Greengard, P., & Gouras, G. K. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64463-x · Cited by 706 · see citing works

Less label, more free: Approaches in label‐free quantitative mass spectrometry

Neilson, K. A., Ali, N., Muralidharan, S., Mirzaei, M., Mariani, M., Assadourian, G., Lee, A., Sluyter, S. C. V., & Haynes, P. A. (2011) · PROTEOMICS · doi:10.1002/pmic.201000553 · Cited by 701 · see citing works

Three dimensions of the amyloid hypothesis: time, space and 'wingmen'

Musiek, E. S., & Holtzman, D. M. (2015) · Nature Neuroscience · doi:10.1038/nn.4018 · Cited by 697 · see citing works

Computational prediction of proteotypic peptides for quantitative proteomics

Mallick, P., Schirle, M., Chen, S. S., Flory, M. R., Lee, H., Martin, D. B., Ranish, J. A., Raught, B., Schmitt, R., Werner, T., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1275 · Cited by 695 · see citing works

Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease

Shi, M., Liu, C., Cook, T. J., Bullock, K. M., Zhao, Y., Ginghina, C., Li, Y., Aro, P., Dator, R., He, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1314-y · Cited by 676 · see citing works

Protein misfolding in neurodegenerative diseases: Implications and strategies

Sweeney, P., Park, H., Baumann, M., Dunlop, J., Frydman, J., Kopito, R., McCampbell, A., Leblanc, G., Venkateswaran, A., Nurmi, A., et al. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0077-5 · Cited by 675 · see citing works

α-Synuclein misfolding and Parkinson's disease

Breydo, L., Wu, J., & Uversky, V. N. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.002 · Cited by 656 · see citing works

Plasma β-amyloid in Alzheimer's disease and vascular disease

Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., et al. (2016) · Scientific Reports · doi:10.1038/srep26801 · Cited by 626 · see citing works

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

Mollenhauer, B., Locascio, J. J., Schulz‐Schaeffer, W., Sixel‐Döring, F., Trenkwalder, C., & Schlossmacher, M. G. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70014-x · Cited by 623 · see citing works

DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease

Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615 · see citing works

Alpha‐synuclein <scp>RT</scp> ‐Qu <scp>IC</scp> in the <scp>CSF</scp> of patients with alpha‐synucleinopathies

Fairfoul, G., McGuire, L. I., Pal, S., Ironside, J. W., Neumann, J., Christie, S., Joachim, C., Esiri, M., Evetts, S. G., Rolinski, M., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.338 · Cited by 608 · see citing works

Neuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease

Price, J. L., Ko, A. I., Wade, M. J., Tsou, S. K., McKeel, D. W., & Morris, J. C. (2001) · Archives of Neurology · doi:10.1001/archneur.58.9.1395 · Cited by 596 · see citing works

Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis

Ovod, V., Ramsey, K. N., Mawuenyega, K. G., Bollinger, J. G., Hicks, T., Schneider, T., Sullivan, M., Paumier, K., Holtzman, D. M., Morris, J. C., et al. (2017) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2017.06.2266 · Cited by 585 · see citing works

Bring on the biomarkers

Poste, G. (2011) · Nature · doi:10.1038/469156a · Cited by 582 · see citing works

Timely Diagnosis for Alzheimer’s Disease: A Literature Review on Benefits and Challenges

Dubois, B., Padovani, A., Scheltens, P., Rossi, A., & Dell’Agnello, G. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150692 · Cited by 565 · see citing works

The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry

Hoofnagle, A. N., & Wener, M. H. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.06.003 · Cited by 562 · see citing works

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease

Hampel, H. J., Bürger, K., Teipel, S. J., Bokde, A. L. W., Zetterberg, H., & Blennow, K. (2007) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.08.006 · Cited by 532 · see citing works

Protein Misfolding Diseases

Hartl, F. U. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-044518 · Cited by 519 · see citing works

Caspase activation precedes and leads to tangles

de Calignon, A., Fox, L. M., Pitstick, R., Carlson, G. A., Bacskai, B. J., Spires-Jones, T. L., & Hyman, B. T. (2010) · Nature · doi:10.1038/nature08890 · Cited by 517 · see citing works

Targeted Proteomic Quantification on Quadrupole-Orbitrap Mass Spectrometer

Gallien, S., Duriez, E., Crone, C., Kellmann, M., Moehring, T., & Domon, B. (2012) · Molecular &amp; Cellular Proteomics · doi:10.1074/mcp.o112.019802 · Cited by 510 · see citing works

Microvesicles as mediators of intercellular communication in cancer—the emerging science of cellular ‘debris’

Lee, T. H., D’Asti, E., Magnus, N., Al-Nedawi, K. N. I., Meehan, B., & Rak, J. W. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0250-3 · Cited by 496 · see citing works

Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid

Shahnawaz, M., Tokuda, T., Waragai, M., Méndez, N., Ishii, R., Trenkwalder, C., Mollenhauer, B., & Soto, C. A. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.4547 · Cited by 485 · see citing works

The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception

Weiner, M. W., Veitch, D. P., Aisen, P. S. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Liu, E., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.09.172 · Cited by 477 · see citing works

Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders

Hall, S., Öhrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., Nilsson, C., Widner, H., Decraemer, H., Nägga, K., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1654 · Cited by 473 · see citing works

Quantitative Proteomics Analysis of the Secretory Pathway

Gilchrist, A., Au, C. E., Hiding, J., Bell, A. W., Fernández-Rodrı́guez, J., Lesimple, S., Nagaya, H., Roy, L., Gosline, S. J. C., Hallett, M. T., et al. (2006) · Cell · doi:10.1016/j.cell.2006.10.036 · Cited by 457 · see citing works

<scp>CSF</scp> A<i>β</i>42/A<i>β</i>40 and A<i>β</i>42/A<i>β</i>38 ratios: better diagnostic markers of Alzheimer disease

Janelidze, S., Zetterberg, H., Mattsson, N., Palmqvist, S., Vanderstichele, H., Lindberg, O., van Westen, D., Stomrud, E., Minthon, L., Blennow, K., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.274 · Cited by 456 · see citing works

Clinico‐Neuropathological Correlation of Alzheimer's Disease in a Community‐Based Case Series

Lim, A., Tsuang, D. W., Kukull, W. A., Nochlin, D., Leverenz, J. B., McCormick, W. C., Bowen, J., Teri, L. L., Thompson, J. C., Peskind, E. R., et al. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb02571.x · Cited by 450 · see citing works

Mass spectrometry-based proteomics: existing capabilities and future directions

Angel, T. E., Aryal, U. K., Hengel, S. M., Baker, E. S., Kelly, R., Robinson, E. W., & Smith, R. D. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15331a · Cited by 443 · see citing works

Alzheimer Disease

Cummings, J. L. (2002) · JAMA · doi:10.1001/jama.287.18.2335 · Cited by 443 · see citing works

Extracellular vesicles in neurodegenerative disease — pathogenesis to biomarkers

Thompson, A. G., Gray, E., Heman-Ackah, S. M., Mäger, I., Talbot, K., Andaloussi, S. E., Wood, M. J., & Turner, M. R. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.68 · Cited by 431 · see citing works

Neuropathology underlying clinical variability in patients with synucleinopathies

Halliday, G. M., Holton, J. L., Révész, T., & Dickson, D. W. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0852-9 · Cited by 426 · see citing works

Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease

Tokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., Locascio, J. J., Schlossmacher, M. G., & El-Agnaf, O. M. A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.024 · Cited by 425 · see citing works

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

Shi, M. Y., Bradner, J. M., Hancock, A. M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J. J., Zabetian, C. P., Kim, H. M., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22311 · Cited by 418 · see citing works

Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC

Groveman, B. R., Orru, C. D., Hughson, A. G., Raymond, L. D., Zanusso, G., Ghetti, B. F., Campbell, K. J., Safar, J., Galasko, D. R., & Caughey, B. W. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0508-2 · Cited by 414 · see citing works

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

Mattsson, N., Andréasson, U., Persson, S., Arai, H., Batish, S. D., Bernardini, S., Bocchio‐Chiavetto, L., Blankenstein, M. A., Carrillo, M. C., Chalbot, S., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.2243 · Cited by 409 · see citing works

Parallel Reaction Monitoring: A Targeted Experiment Performed Using High Resolution and High Mass Accuracy Mass Spectrometry

Rauniyar, N. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226120 · Cited by 406 · see citing works

Biomarkers of Parkinson’s disease: Present and future

Miller, D. B., & O'Callaghan, J. P. (2014) · Metabolism · doi:10.1016/j.metabol.2014.10.030 · Cited by 403 · see citing works

Extracellular vesicles: novel promising delivery systems for therapy of brain diseases.

Rufino-Ramos, D., Albuquerque, P. R., Carmona, V., Perfeito, R., Nobre, R. J., & Pereira de Almeida, L. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.001 · Cited by 395 · see citing works

Identification and Relative Quantitation of Protein Mixtures by Enzymatic Digestion Followed by Capillary Reversed-Phase Liquid Chromatography−Tandem Mass Spectrometry

Bondarenko, P. V., Chelius, D., & Shaler, T. A. (2002) · Analytical Chemistry · doi:10.1021/ac0256991 · Cited by 390 · see citing works

Total and phosphorylated tau protein as biological markers of Alzheimer’s disease

Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.010 · Cited by 389 · see citing works

Plasma tau levels in Alzheimer's disease

Zetterberg, H., Wilson, D. H., Andréasson, U., Minthon, L., Blennow, K., Randall, J., & Hansson, O. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt163 · Cited by 385 · see citing works

CSF biomarker variability in the Alzheimer's Association quality control program

Mattsson, N., Andréasson, U., Persson, S., Carrillo, M. C., Collins, S. J., Chalbot, S., Cutler, N. E., Dufour‐Rainfray, D., Fagan, A. M., Heegaard, N. H. H., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.010 · Cited by 383 · see citing works

CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease

Siderowf, A. D., Xie, S. X., Hurtig, H. I., Weintraub, D. A., Duda, J. E., Chen‐Plotkin, A. S., Shaw, L. M. J., Deerlin, V. M. V., Trojanowski, J. Q., & Clark, C. N. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f39a78 · Cited by 379 · see citing works

High complement levels in astrocyte‐derived exosomes of Alzheimer disease

Goetzl, E. J., Schwartz, J. B., Abner, E. L., Jicha, G. A., & Kapogiannis, D. (2018) · Annals of Neurology · doi:10.1002/ana.25172 · Cited by 369 · see citing works

Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease

Kang, J. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3861 · Cited by 366 · see citing works

A targeted proteomics–based pipeline for verification of biomarkers in plasma

Whiteaker, J. R., Lin, C., Kennedy, J. J., Hou, L., Trute, M., Sokal, I., Yan, P., Schoenherr, R. M., Zhao, L., Voytovich, U. J., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1900 · Cited by 365 · see citing works

Proteomics beyond trypsin

Tsiatsiani, L., & Heck, A. J. R. (2015) · FEBS Journal · doi:10.1111/febs.13287 · Cited by 353 · see citing works

A review on mass spectrometry-based quantitative proteomics: Targeted and data independent acquisition

Vidová, V., & Spáčil, Z. (2017) · Analytica Chimica Acta · doi:10.1016/j.aca.2017.01.059 · Cited by 353 · see citing works

Role of post-translational modifications in modulating the structure, function and toxicity of α-synuclein

Oueslati, A., Fournier, M., & Lashuel, H. A. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)83007-9 · Cited by 340 · see citing works

On the Development of Plasma Protein Biomarkers

Surinova, S., Schiess, R., Hüttenhain, R., Cerciello, F., Wollscheid, B., & Aebersold, R. (2011) · Journal of Proteome Research · doi:10.1021/pr1008515 · Cited by 334 · see citing works

Phosphorylation at S87 Is Enhanced in Synucleinopathies, Inhibits α-Synuclein Oligomerization, and Influences Synuclein-Membrane Interactions

Paleologou, K. E., Oueslati, A., Shakked, G., Rospigliosi, C. C., Kim, H., Lamberto, G. R., Fernández, C. O., Schmid, A. W., Chegini, F., Gai, W., et al. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.5922-09.2010 · Cited by 324 · see citing works

Hippocampal neurons in pre-clinical Alzheimer's disease.

West, M. J., Kawas, C. H., Stewart, W. F., Rudow, G. L., & Troncoso, J. C. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.005 · Cited by 317 · see citing works

The future of blood‐based biomarkers for Alzheimer's disease

Henriksen, K., O’Bryant, S. E., Hampel, H. J., Trojanowski, J. Q., Montine, T. J., Jeromin, A., Blennow, K., Lönneborg, A., Wyss‐Coray, T., Soares, H. D., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.013 · Cited by 312 · see citing works

Parallel reaction monitoring using quadrupole‐Orbitrap mass spectrometer: Principle and applications

Bourmaud, A., Gallien, S., & Domon, B. (2016) · PROTEOMICS · doi:10.1002/pmic.201500543 · Cited by 311 · see citing works

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects

Trojanowski, J. Q., Vandeerstichele, H., Korecka, M., Clark, C. M., Aisen, P. S. S., Petersen, R. C., Blennow, K., Soares, H. D., Simon, A. J., Lewczuk, P., et al. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.03.008 · Cited by 308 · see citing works

Transmission of α-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson’s disease?

Matsumoto, J., Stewart, T., Sheng, L., Li, N., Bullock, K. M., Song, N., Shi, M. Y., Banks, W. A., & Zhang, J. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0470-4 · Cited by 294 · see citing works

Advances in mass spectrometry-based clinical biomarker discovery

Crutchfield, C. A., Thomas, S. N., Sokoll, L. J., & Chan, D. W. (2016) · Clinical Proteomics · doi:10.1186/s12014-015-9102-9 · Cited by 291 · see citing works

Exosomes in the Pathology of Neurodegenerative Diseases

Howitt, J. A., & Hill, A. F. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.757955 · Cited by 287 · see citing works

Quantitative Analysis of Bacterial and Mammalian Proteomes Using a Combination of Cysteine Affinity Tags and 15N-Metabolic Labeling

Conrads, T. P., Alving, K., Veenstra, T. D., Belov, M. E., Anderson, G., Anderson, D. J., Lipton, M. S. W., Paša-Tolić, L., Udseth, H. R., Chrisler, W., et al. (2001) · Analytical Chemistry · doi:10.1021/ac001487x · Cited by 286 · see citing works

Selected reaction monitoring applied to proteomics

Gallien, S., Duriez, E., & Domon, B. (2011) · Journal of Mass Spectrometry · doi:10.1002/jms.1895 · Cited by 285 · see citing works

Phosphorylated α-Synuclein in Parkinson’s Disease

Wang, Y., Shi, M. Y., Chung, K. A., Zabetian, C. P., Leverenz, J. B., Berg, D., Srulijes, K., Trojanowski, J. Q., Lee, V. M. ‐., Siderowf, A. D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002566 · Cited by 281 · see citing works

Differential Mass Spectrometry: A Label-Free LC−MS Method for Finding Significant Differences in Complex Peptide and Protein Mixtures

Wiener, M. C., Sachs, J. R., Deyanova, E. G., & Yates, N. A. (2004) · Analytical Chemistry · doi:10.1021/ac0493875 · Cited by 273 · see citing works

Proteome analysis of human substantia nigra in Parkinson's disease

Basso, M., Giraudo, S., Corpillo, D., Bergamasco, B., Lopiano, L., & Fasano, M. (2004) · PROTEOMICS · doi:10.1002/pmic.200400848 · Cited by 271 · see citing works

Stable isotope labelling methods in mass spectrometry-based quantitative proteomics

Chahrour, O., Cobice, D., & Malone, J. (2015) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2015.04.013 · Cited by 267 · see citing works

The Transport Mechanism of Extracellular Vesicles at the Blood-Brain Barrier

Matsumoto, J., Stewart, T., Banks, W. A., & Zhang, J. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612823666170913164738 · Cited by 267 · see citing works

Cerebrospinal Fluid Aβ 42/40 Corresponds Better than Aβ 42 to Amyloid PET in Alzheimer’s Disease

Lewczuk, P., Matzen, A., Blennow, K., Parnetti, L., Molinuevo, J. L., Eusebi, P., Kornhuber, J., Morris, J. C., & Fagan, A. M. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160722 · Cited by 263 · see citing works

Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents

Jouanne, M., Rault, S., & Voisin‐Chiret, A. S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.070 · Cited by 252 · see citing works

The economic impact of Parkinson's disease

Findley, L. J. J. (2007) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.06.003 · Cited by 249 · see citing works

Diagnostic Criteria for Parkinson’s Disease: From James Parkinson to the Concept of Prodromal Disease

Marsili, L., Rizzo, G., & Colosimo, C. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00156 · Cited by 244 · see citing works

The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy

Lee, P. H., Lee, G., Park, H. J., Bang, O. Y., Joo, I. S., & Huh, K. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-005-0427-9 · Cited by 242 · see citing works

Mass spectrometry based biomarker discovery, verification, and validation — Quality assurance and control of protein biomarker assays

Parker, C. E., & Borchers, C. H. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.03.006 · Cited by 238 · see citing works

CSF biomarkers and clinical progression of Parkinson disease

Hall, S., Surova, Y., Öhrfelt, A., Zetterberg, H., Lindqvist, D., & Hansson, O. (2014) · Neurology · doi:10.1212/wnl.0000000000001098 · Cited by 236 · see citing works

The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline

Paulovich, A. G., Whiteaker, J. R., Hoofnagle, A. N., & Wang, P. (2008) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200780174 · Cited by 229 · see citing works

Endovascular therapy for the carotid blowout syndrome in head and neck surgical patients: diagnostic and managerial considerations.

Chaloupka, J. C., Putman, C. M., Citardi, M. J., Ross, D. A., & Sasaki, C. T. (1996) · PubMed Central · Cited by 229 · see citing works

Proteomic Identification of a Stress Protein, Mortalin/mthsp70/GRP75

Jin, J., Hulette, C., Wang, Y., Zhang, T., Pan, C., Wadhwa, R., & Zhang, J. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500382-mcp200 · Cited by 228 · see citing works

Emerging Role of Neuronal Exosomes in the Central Nervous System

Chivet, M., Hemming, F. J., Pernet‐Gallay, K., Fraboulet, S., & Sadoul, R. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00145 · Cited by 223 · see citing works

Challenges in biomarker discovery: combining expert insights with statistical analysis of complex omics data

McDermott, J., Wang, J., Mitchell, H. D., Webb‐Robertson, B., Hafen, R., Ramey, J., & Rodland, K. (2012) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2012.718329 · Cited by 221 · see citing works

Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum

Shi, T., Fillmore, T., Sun, X., Zhao, R., Schepmoes, A., Hossain, M., Xie, F., Wu, S., Kim, J., Jones, N., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204366109 · Cited by 220 · see citing works

Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease

Podlesniy, P., Figueiro‐Silva, J., Llado, A., Antonell, A., Sanchez‐Valle, R., Alcolea, D., Lleo, A., Molinuevo, J. L., Serra, N., & Trullas, R. (2013) · Annals of Neurology · doi:10.1002/ana.23955 · Cited by 219 · see citing works

Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease

Shi, M. Y., Zabetian, C. P., Hancock, A. M., Ginghină, C., Hong, Z., Yearout, D., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D. R., et al. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.06.009 · Cited by 219 · see citing works

Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study

Nurmi, E., Ruottinen, H., Bergman, J. R., Haaparanta‐Solin, M., Solin, O. H., Sonninen, P. H., & Rinne, J. O. (2001) · Movement Disorders · doi:10.1002/mds.1139 · Cited by 219 · see citing works

Personalized medicine using DNA biomarkers: a review

Ziegler, A., Koch, A., Krockenberger, K., & Großhennig, A. (2012) · Human Genetics · doi:10.1007/s00439-012-1188-9 · Cited by 213 · see citing works

Parallel reaction monitoring (PRM) and selected reaction monitoring (SRM) exhibit comparable linearity, dynamic range and precision for targeted quantitative HDL proteomics

Ronsein, G. E., Pamir, N., von Haller, P. D., Kim, D. S., Oda, M. N., Jarvik, G. P., Vaisar, T., & Heinecke, J. W. (2014) · Journal of Proteomics · doi:10.1016/j.jprot.2014.10.017 · Cited by 213 · see citing works

Alpha-synuclein Post-translational Modifications as Potential Biomarkers for Parkinson Disease and Other Synucleinopathies

Schmid, A. W., Fauvet, B., Moniatte, M., & Lashuel, H. A. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r113.032730 · Cited by 212 · see citing works

CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)

Ritchie, C. W., Smailagic, N., Noel-Storr, A. H., Ukoumunne, O. C., Ladds, E. C., & Martin, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010803.pub2 · Cited by 208 · see citing works

Extracellular vesicles – Their role in the packaging and spread of misfolded proteins associated with neurodegenerative diseases

Coleman, B. M., & Hill, A. F. (2015) · Seminars in Cell &amp; Developmental Biology · doi:10.1016/j.semcdb.2015.02.007 · Cited by 208 · see citing works

CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease

Shi, M., Kovac, A., Korff, A., Cook, T. J., Ginghina, C., Bullock, K. M., Yang, L., Stewart, T., Zheng, D., Aro, P., et al. (2016) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2016.04.003 · Cited by 206 · see citing works

Metabolic Labeling of Proteins for Proteomics

Beynon, R. J., & Pratt, J. M. (2005) · Molecular &amp; Cellular Proteomics · doi:10.1074/mcp.r400010-mcp200 · Cited by 205 · see citing works

Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson’s disease

Waragai, M., Wei, J., Fujita, M., Nakai, M., Ho, G. J., Masliah, E., Akatsu, H., Yamada, T., & Hashimoto, M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.011 · Cited by 195 · see citing works

Label-free Quantitative Proteomics Using Large Peptide Data Sets Generated by Nanoflow Liquid Chromatography and Mass Spectrometry

Ono, M., Shitashige, M., Honda, K., Isobe, T., Kuwabara, H., Matsuzuki, H., Hirohashi, S., & Yamada, T. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.t500039-mcp200 · Cited by 195 · see citing works

Targeted proteomics for quantification of histone acetylation in A lzheimer's disease

Zhang, K., Schrag, M., Crofton, A. R., Trivedi, R. K., Vinters, H. V., & Kirsch, W. M. (2012) · PROTEOMICS · doi:10.1002/pmic.201200010 · Cited by 191 · see citing works

False Discovery Rates of Protein Identifications: A Strike against the Two-Peptide Rule

Gupta, N., & Pevzner, P. A. (2009) · Journal of Proteome Research · doi:10.1021/pr9004794 · Cited by 188 · see citing works

Amyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study

Koivunen, J., Scheinin, N., Virta, J. R., Aalto, S., Vahlberg, T., Någren, K., Helin, S., Parkkola, R., Viitanen, M., & Rinne, J. O. (2011) · Neurology · doi:10.1212/wnl.0b013e318212015e · Cited by 188 · see citing works

Cerebrospinal tau, phospho‐tau, and beta‐amyloid and neuropsychological functions in Parkinson's disease

Compta, Y., Martı́, M. J., Ibarretxe‐Bilbao, N., Junqué, C., Valldeoriola, F., Muñoz, E., Ezquerra, M., Ríos, J., & TOLOSA, E. S. (2009) · Movement Disorders · doi:10.1002/mds.22594 · Cited by 185 · see citing works

How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease

Püntmann, V. O. (2009) · Postgraduate Medical Journal · doi:10.1136/pgmj.2008.073759 · Cited by 184 · see citing works

CSF Aβ42 and tau in Parkinson's disease with cognitive impairment

Montine, T. J., Shi, M. Y., Quinn, J. F., Peskind, E. R., Craft, S., Ginghină, C., Chung, K. A., Kim, H., Galasko, D. R., Jankovic, J. J., et al. (2010) · Movement Disorders · doi:10.1002/mds.23287 · Cited by 182 · see citing works

Blood-Based Biomarkers of Alzheimer's Disease: Challenging but Feasible

Thambisetty, M., & Lovestone, S. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.84 · Cited by 182 · see citing works

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease

Parnetti, L., Farotti, L., Eusebi, P., Chiasserini, D., Carlo, C. D., Giannandrea, D., Salvadori, N., Lisetti, V., Tambasco, N., Rossi, A., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00053 · Cited by 177 · see citing works

Developing novel blood‐based biomarkers for Alzheimer's disease

Snyder, H. M., Carrillo, M. C., Grodstein, F., Henriksen, K., Jeromin, A., Lovestone, S., Mielke, M. M., O'Bryant, S., Sarasa, M., Sj⊘gren, M., et al. (2014) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2013.10.007 · Cited by 177 · see citing works

Increased Selectivity, Analytical Precision, and Throughput in Targeted Proteomics

Kiyonami, R., Schoen, A. E., Prakash, A., Peterman, S. M., Zabrouskov, V., Picotti, P., Aebersold, R. H., Hühmer, A. F. R., & Domon, B. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.002931 · Cited by 177 · see citing works

Post-translational modification of α-synuclein in Parkinson׳s disease

Barrett, P. J., & Greenamyre, J. T. (2015) · Brain Research · doi:10.1016/j.brainres.2015.06.002 · Cited by 175 · see citing works

Plasma biomarkers for mild cognitive impairment and Alzheimer's disease

Song, F., Poljak, A., Smythe, G. A., & Sachdev, P. S. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.003 · Cited by 173 · see citing works

Cerebrospinal fluid Tau/α‐synuclein ratio in Parkinson's disease and degenerative dementias

Parnetti, L., Chiasserini, D., Bellomo, G., Giannandrea, D., Carlo, C. D., Qureshi, M. M., Ardah, M. T., Varghese, S., Bonanni, L., Borroni, B., et al. (2011) · Movement Disorders · doi:10.1002/mds.23670 · Cited by 170 · see citing works

The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson’s disease

Broussolle, E., Dentresangle, C., Landais, P., Garcı́a-Larrea, L., Pollak, P., Croisile, B., Hibert, O., Bonnefoi, F., Galy, G., Froment, J. C., et al. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00127-6 · Cited by 169 · see citing works

Dissection of Proteolytic 18O Labeling: Endoprotease-Catalyzed 16O-to-18O Exchange of Truncated Peptide Substrates

Yao, X., Afonso, C., & Fenselau, C. (2002) · Journal of Proteome Research · doi:10.1021/pr025572s · Cited by 168 · see citing works

The Bottleneck in the Cancer Biomarker Pipeline and Protein Quantification through Mass Spectrometry–Based Approaches: Current Strategies for Candidate Verification

Makawita, S., & Diamandis, E. P. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.127019 · Cited by 168 · see citing works

Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases

Sheinerman, K. S., Toledo, J. B., Tsivinsky, V. G., Irwin, D. J., Grossman, M., Weintraub, D. A., Hurtig, H. I., Chen‐Plotkin, A. S., Wolk, D. A., McCluskey, L. F., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0316-0 · Cited by 168 · see citing works

Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease

Zabetian, C. P., Hutter, C. M., Factor, S. A., Nutt, J. G., Higgins, D. S., Griffith, A., Roberts, J. W., Leis, B. C., Kay, D. M., Yearout, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21157 · Cited by 165 · see citing works

Mass spectrometry‐based targeted quantitative proteomics: Achieving sensitive and reproducible detection of proteins

Boja, E. S., & Rodriguez, H. (2012) · PROTEOMICS · doi:10.1002/pmic.201100387 · Cited by 165 · see citing works

Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF

Spellman, D. S., Wildsmith, K. R., Honigberg, L. A., Tuefferd, M., Baker, D., Raghavan, N., Nairn, A. C., Croteau, P., Schirm, M., Allard, R., et al. (2015) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201400178 · Cited by 161 · see citing works

Plasma α-synuclein is decreased in subjects with Parkinson's disease

Li, Q., Mok, S. S., Laughton, K. M., McLean, C., Cappai, R., Masters, C. L., Culvenor, J. G., & Horne, M. K. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.12.006 · Cited by 160 · see citing works

Mass Spectrometry–Based Candidate Reference Measurement Procedure for Quantification of Amyloid-β in Cerebrospinal Fluid

Leinenbach, A., Pannee, J., Dülffer, T., Huber, A., Bittner, T., Andréasson, U., Gobom, J., Zetterberg, H., Kobold, U., Portelius, E., et al. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2013.220392 · Cited by 158 · see citing works

Accurate Inclusion Mass Screening

Jaffe, J. D., Keshishian, H., Chang, B., Addona, T. A., Gillette, M. A., & Carr, S. A. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800218-mcp200 · Cited by 154 · see citing works

Exosomes in Alzheimer's disease

Malm, T., Loppi, S. H., & Kanninen, K. M. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.04.011 · Cited by 152 · see citing works

Changes in the Chemical Barrier Composition of Tears in Alzheimer’s Disease Reveal Potential Tear Diagnostic Biomarkers

Kalló, G., Emri, M., Varga, Z., Ujhelyi, B., Tőzsér, J., Csutak, A., & Csősz, É. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158000 · Cited by 152 · see citing works

Accumulation of Aspartic Acid 421 - and Glutamic Acid 391 -Cleaved Tau in Neurofibrillary Tangles Correlates With Progression in Alzheimer Disease

Basurto‐Islas, G., Luna‐Muñoz, J., Guillozet-Bongaarts, A. L., Binder, L. I., Mena, R., & García‐Sierra, F. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31817275c7 · Cited by 150 · see citing works

Neuroimaging Biomarkers of Neurodegenerative Diseases and Dementia

Risacher, S. L., & Saykin, A. J. (2013) · Seminars in Neurology · doi:10.1055/s-0033-1359312 · Cited by 149 · see citing works

Trypsin catalyzed 16O-to-18O exchange for comparative proteomics: Tandem mass spectrometry comparison using MALDI-TOF, ESI-QTOF, and ESI-ion trap mass spectrometers

Heller, M., Mattou, H., Menzel, C., & Yao, X. (2003) · Journal of the American Society for Mass Spectrometry · doi:10.1016/s1044-0305(03)00207-1 · Cited by 147 · see citing works

Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics

Wildsmith, K. R., Schauer, S. P., Smith, A. M., Arnott, D. P., Zhu, Y., Haznedar, J., Kaur, S., Mathews, W. R., & Honigberg, L. A. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-22 · Cited by 140 · see citing works

Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer’s Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies

Barthélemy, N. R., Gabelle, A., Hirtz, C., Fenaille, F., Sergeant, N., Schraen-Maschke, S., Vialaret, J., Buée, L., Junot, C., Becher, F., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150962 · Cited by 139 · see citing works

Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot

Hampel, H. J., Lista, S., & Khachaturian, Z. S. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.2116 · Cited by 138 · see citing works

Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development

Frantzi, M., Bhat, A. V., & Latosińska, A. (2014) · Clinical and Translational Medicine · doi:10.1186/2001-1326-3-7 · Cited by 137 · see citing works

Incorrect Diagnosis of Alzheimer's Disease: A Clinicopathologic Study

Klatka, L. A. (1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550010045015 · Cited by 136 · see citing works

Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer′s and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies

Oeckl, P., Metzger, F., Nagl, M., Arnim, C. A. F. V., Halbgebauer, S., Steinacker, P., Ludolph, A. C., & Otto, M. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.059915 · Cited by 135 · see citing works

Models of α-synuclein aggregation in Parkinson’s disease

Giráldez‐Pérez, R. M., Antolín‐Vallespín, M., Muñoz, M.-D., & Sánchez‐Capelo, A. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0176-9 · Cited by 134 · see citing works

CSF Aβ1–42 – an excellent but complicated Alzheimer's biomarker – a route to standardisation

Kuhlmann, J., Andréasson, U., Pannee, J., Bjerke, M., Portelius, E., Leinenbach, A., Bittner, T., Korecka, M., Jenkins, R. G., Vanderstichele, H., et al. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.05.014 · Cited by 134 · see citing works

Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years

Hertze, J., Minthon, L., Zetterberg, H., Vanmechelen, E., Blennow, K., & Hansson, O. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100207 · Cited by 132 · see citing works

Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease

Rembach, A., Faux, N. G., Watt, A. D., Pertile, K. K., Rumble, R. L., Trounson, B. O., Fowler, C. J., Roberts, B. R., Perez, K. A., Li, Q., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.12.006 · Cited by 132 · see citing works

CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease

Abdo, W. F., Bloem, B. R., van Geel, W. J. A., Esselink, R. A. J., & Verbeek, M. M. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.010 · Cited by 130 · see citing works

Tau gene and Parkinson's disease: a case-control study and meta-analysis

Healy, D. G. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.026203 · Cited by 125 · see citing works

Glycoproteomics in neurodegenerative diseases

Hwang, H., Zhang, J., Chung, K. A., Leverenz, J. B., Zabetian, C. P., Peskind, E. R., Jankovic, J. J., Su, Z., Hancock, A. M., Pan, C., et al. (2009) · Mass Spectrometry Reviews · doi:10.1002/mas.20221 · Cited by 124 · see citing works

Tissue transglutaminase catalyzes the formation of alpha‐synuclein crosslinks in Parkinson's disease

Andringa, G., Lam, K., Chegary, M., Wang, X., Chase, T. N., & Bennett, M. C. (2004) · The FASEB Journal · doi:10.1096/fj.03-0829fje · Cited by 123 · see citing works

Levodopa: A new look at an old friend

Olanow, C. W., & Stocchi, F. (2017) · Movement Disorders · doi:10.1002/mds.27216 · Cited by 120 · see citing works

Post-Translational Modifications of Exosomal Proteins

Moreno-Gonzalo, O., Villarroya‐Beltri, C., & Sánchez‐Madrid, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00383 · Cited by 118 · see citing works

Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change

Soldan, A., Pettigrew, C. A., Cai, Q., Wang, M., Moghekar, A., O’Brien, R., Selnes, O. A., & Albert, M. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0194 · Cited by 117 · see citing works

The development of selected reaction monitoring methods for targeted proteomics via empirical refinement

Bereman, M. S., MacLean, B., Tomazela, D. M., Liebler, D. C., & MacCoss, M. J. (2012) · PROTEOMICS · doi:10.1002/pmic.201200042 · Cited by 116 · see citing works

Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease

Waragai, M., Nakai, M., Wei, J., Fujita, M., Mizuno, H., Ho, G. J., Masliah, E., Akatsu, H., Yokochi, F., & Hashimoto, M. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.08.010 · Cited by 114 · see citing works

Recent developments in biomarkers in Parkinson disease

Schapira, A. H. V. (2013) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283633741 · Cited by 112 · see citing works

Qualification of a Surrogate Matrix-Based Absolute Quantification Method for Amyloid-β42 in Human Cerebrospinal Fluid Using 2D UPLC-Tandem Mass Spectrometry

Korecka, M., Waligórska, T., Figurski, M., Toledo, J. B., Arnold, S. E., Grossman, M., Trojanowski, J. Q., & Shaw, L. M. J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132489 · Cited by 112 · see citing works

Plasma α‐synuclein in patients with Parkinson's disease with and without treatment

Durán, R., Barrero, F. J., Morales, B., Luna, J. D. D., Ramírez, M. R., & Vives, F. (2010) · Movement Disorders · doi:10.1002/mds.22928 · Cited by 111 · see citing works

Automated MRI measures predict progression to Alzheimer's disease

Desikan, R. S., Cabral, H., Settecase, F., Hess, C. P., Dillon, W. P., Glastonbury, C. M., Weiner, M. W., Schmansky, N. J., Salat, D. H., & Fischl, B. R. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.023 · Cited by 110 · see citing works

DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease

Lin, X., Cook, T. J., Zabetian, C. P., Leverenz, J. B., Peskind, E. R., Hu, S., Cain, K. C., Pan, C., Edgar, J. S., Goodlett, D. R., et al. (2012) · Scientific Reports · doi:10.1038/srep00954 · Cited by 110 · see citing works

Targeted mass spectrometry approaches for protein biomarker verification

Meng, Z., & Veenstra, T. D. (2011) · Journal of Proteomics · doi:10.1016/j.jprot.2011.04.011 · Cited by 107 · see citing works

A Selected Reaction Monitoring (SRM)-Based Method for Absolute Quantification of Aβ ₃₈ , Aβ ₄₀ , and Aβ ₄₂ in Cerebrospinal Fluid of Alzheimer's Disease Patients and Healthy Controls

Pannee, J., Portelius, E., Oppermann, M., Atkins, A., Hornshaw, M., Zegers, I., Höjrup, P., Minthon, L., Hansson, O., Zetterberg, H., et al. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2012-121471 · Cited by 105 · see citing works

CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease

Terrelonge, M., Marder, K. S., Weintraub, D. A., & Alcalay, R. N. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0647-x · Cited by 102 · see citing works

Severe nigrostriatal degeneration without clinical parkinsonism in patients with polymerase gamma mutations

Tzoulis, C., Tran, G. T., Schwarzlmüller, T., Specht, K., Haugarvoll, K., Balafkan, N., Lilleng, P. K., Miletić, H., Biermann, M., & Bindoff, L. A. (2013) · Brain · doi:10.1093/brain/awt103 · Cited by 102 · see citing works

α-Synuclein Multistate Folding Thermodynamics: Implications for Protein Misfolding and Aggregation

Ferreon, A. C. M., & Deniz, A. A. (2007) · Biochemistry · doi:10.1021/bi602461y · Cited by 100 · see citing works

Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity

Stewart, T., Sossi, V., Aasly, J. O., Wszołek, Z. K., Uitti, R. J., Hasegawa, K., Yokoyama, T., Zabetian, C. P., Leverenz, J. B., Stoessl, A. J., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0185-3 · Cited by 100 · see citing works

Characteristics of patients misdiagnosed with Alzheimer’s disease and their medication use: an analysis of the NACC-UDS database

Gaugler, J. E., Ascher-Svanum, H., Roth, D. L., Fafowora, T., Siderowf, A., & Beach, T. G. (2013) · BMC Geriatrics · doi:10.1186/1471-2318-13-137 · Cited by 97 · see citing works

α-Synuclein in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment

Korff, A., Liu, C., Ginghina, C., Shi, M., Zhang, J., & Initiative, F. T. A. D. N. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-130458 · Cited by 95 · see citing works

Secretion of DJ-1 into the serum of patients with Parkinson's disease

Maita, C., Tsuji, S., Yabe, I., Hamada, S., Ogata, A., Maita, H., Iguchi‐Ariga, S. M. M., Sasaki, H., & Ariga, H. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.11.027 · Cited by 94 · see citing works

Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment

Boccardi, M., Altomare, D., Ferrari, C., Festari, C., Guerra, U. P., Paghera, B., Pizzocaro, C., Lussignoli, G., Geroldi, C., Zanetti, O. O., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3751 · Cited by 94 · see citing works

The Cerebrospinal Fluid Aβ 1–42 /Aβ 1–40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer’s Disease in a Clinical Setting

Niemantsverdriet, E., Ottoy, J., Somers, C., Roeck, E. E. D., Struyfs, H., Soetewey, F., Verhaeghe, J. A. J., den Bossche, T. V., Mossevelde, S. V., Goeman, J., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170327 · Cited by 94 · see citing works

α-Synuclein and Lewy pathology in Parkinson's disease

Kalia, L. V., & Kalia, S. K. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000215 · Cited by 93 · see citing works

Biomarkers in Neurodegenerative Diseases

Jeromin, A., & Bowser, R. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-57193-5_20 · Cited by 92 · see citing works

Development of MRM-Based Assays for the Absolute Quantitation of Plasma Proteins

Kuzyk, M. A., Parker, C. E., Domański, D., & Borchers, C. H. (2013) · Methods in molecular biology · doi:10.1007/978-1-4614-7209-4_4 · Cited by 90 · see citing works

Applications of Tandem Mass Spectrometry (MS/MS) in Protein Analysis for Biomedical Research

Neagu, A.-N., Jayathirtha, M., Baxter, E., Donnelly, M., Petre, B. A., & Darie, C. C. (2022) · Molecules · doi:10.3390/molecules27082411 · Cited by 143 · see citing works

Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau

Rayaprolu, S., Higginbotham, L., Bagchi, P., Watson, C. M., Zhang, T., Levey, A. I., Rangaraju, S., & Seyfried, N. T. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00840-3 · Cited by 118 · see citing works

Cancer protein biomarker discovery based on nucleic acid aptamers

Xiong, H., Yan, J., Cai, S., He, Q., Peng, D., Liu, Z., & Liu, Y. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.03.165 · Cited by 81 · see citing works

Mass spectrometry‐based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids

Korecka, M., & Shaw, L. M. J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15465 · Cited by 79 · see citing works

Mechanistic insight into female predominance in Alzheimer’s disease based on aberrant protein S-nitrosylation of C3

Yang, H., Oh, C.-K., Amal, H., Wishnok, J. S., Lewis, S., Schahrer, E., Trudler, D., Nakamura, T., Tannenbaum, S. R., & Lipton, S. A. (2022) · Science Advances · doi:10.1126/sciadv.ade0764 · Cited by 70 · see citing works

Morphologically Flex Sm-MOF Based Electrochemical Immunosensor for Ultrasensitive Detection of a Colon Cancer Biomarker

Biswas, S., Lan, Q., Li, C., & Xia, X. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c05538 · Cited by 69 · see citing works

Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson’s disease patient fibroblasts

Korecka, J. A., Thomas, R., Christensen, D. P., Hinrich, A. J., Ferrari, E. J., Levy, S. A., Hastings, M. L., Hallett, P. J., & Ole Isacson, A. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz126 · Cited by 65 · see citing works

Global, in situ analysis of the structural proteome in individuals with Parkinson’s disease to identify a new class of biomarker

Mackmull, M., Nagel, L., Sesterhenn, F., Muntel, J., Großbach, J., Stalder, P., Bruderer, R., Reiter, L., van de Berg, W. D. J., de Souza, N., et al. (2022) · Nature Structural & Molecular Biology · doi:10.1038/s41594-022-00837-0 · Cited by 53 · see citing works

Application of multi-omics in the study of traditional Chinese medicine

Zhao, M., Che, Y., Gao, Y., & Zhang, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1431862 · Cited by 52 · see citing works

Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg

Obrocki, P., Khatun, A., Ness, D., Senkevich, K. A., Hanrieder, J., Capraro, F., Mattsson, N., Andréasson, U., Portelius, E., Ashton, N. J., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00586-6 · Cited by 51 · see citing works

DNAzyme-based faithful probing and pulldown to identify candidate biomarkers of low abundance

Hu, Q., Tong, Z.-X., Yalikong, A., Ge, L., Shi, Q., Du, X., Wang, P., Liu, X., Zhan, W., Gao, X., et al. (2023) · Nature Chemistry · doi:10.1038/s41557-023-01328-5 · Cited by 45 · see citing works

Analytical Chemistry in the 21st Century: Challenges, Solutions, and Future Perspectives of Complex Matrices Quantitative Analyses in Biological/Clinical Field

Merone, G. M., Tartaglia, A., Locatelli, M., D’Ovidio, C., Rosato, E., de Grazia, U., Santavenere, F., Rossi, S., & Savini, F. (2020) · Analytica—A Journal of Analytical Chemistry and Chemical Analysis · doi:10.3390/analytica1010006 · Cited by 33 · see citing works

Glycoproteins as diagnostic and prognostic biomarkers for neurodegenerative diseases: A glycoproteomic approach

Xu, M., Zhou, M., Li, S., Zhen, X., & Yang, S. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24805 · Cited by 27 · see citing works

Study on Ammonia Content and Distribution in the Microenvironment Based on Covalent Organic Framework Nanochannels

Ahmed, S. A., Xing, X.-L., Liao, Q., Li, Z., Li, C., Xi, K., Wang, K., & Xia, X. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c01692 · Cited by 21 · see citing works

Identification of the target protein of the metastatic colorectal cancer-specific aptamer W3 as a biomarker by aptamer-based target cells sorting and functional characterization

Li, W., Wu, C., Wang, S., Zhou, L., Qiao, L., Ba, W., Liu, F., Zhan, L., Chen, H., Yu, J., et al. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114451 · Cited by 20 · see citing works

Novel biomarkers in Alzheimer’s disease using high resolution proteomics and metabolomics: miRNAS, proteins and metabolites

Navas-Carrillo, D., Rivera‐Caravaca, J. M., Sampedro-Andrada, A., & Orenes‐Piñero, E. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2020.1833298 · Cited by 19 · see citing works

Cerebrospinal Fluid Biomarkers in Childhood Leukemias

Ikonomidou, C. (2021) · Cancers · doi:10.3390/cancers13030438 · Cited by 19 · see citing works

“Advances in biomarker discovery and diagnostics for alzheimer’s disease”

Bhatia, V., Chandel, A., Minhas, Y., & Kushawaha, S. K. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08023-y · Cited by 21 · see citing works

Recent Advances in Mass Spectrometry-Based Studies of Post-Translational Modifications in Alzheimer’s Disease

Wu, F., Li, W., Lu, H., & Li, L. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.101003 · Cited by 16 · see citing works

A Quantitative LC-MS/MS Method for Distinguishing the Tau Protein Forms Phosphorylated and Nonphosphorylated at Serine-396

Jacobsen, A., van de Merbel, N. C., Ditlevsen, D. K., Tvermosegaard, K., Schalk, F., Lambert, W., Bundgaard, C., Pedersen, J. T., & Rosenqvist, N. (2023) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.2c00324 · Cited by 15 · see citing works

Data-driven biomarker analysis using computational omics approaches to assess neurodegenerative disease progression

Krokidis, M. G., Exarchos, T. P., & Vlamos, P. (2021) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2021094 · Cited by 14 · see citing works

Proteomics identifies lipocalin-2 in neonatal inflammation associated with cerebrovascular alteration in mice and preterm infants

Gravina, G., Ardalan, M., Chumak, T., Nilsson, A., Ek, J. C., Danielsson, H., Svedin, P., Pekny, M., Pekna, M., Sävman, K., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107217 · Cited by 13 · see citing works

Applications of spatially resolved omics in the field of endocrine tumors

Hou, Y., Gao, Y., Guo, S., Zhang, Z., Chen, R., & Zhang, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.993081 · Cited by 12 · see citing works

Systematic review and meta-analysis of human health-related protein markers for realizing real-time wastewater-based epidemiology

Devianto, L. A., & Sano, D. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.165304 · Cited by 12 · see citing works

Mass spectrometry based protein biomarkers and drug target discovery and clinical diagnosis in Age-Related progressing neurodegenerative diseases

Agrawal, I., Tripathi, P., & Biswas, S. (2022) · Drug Metabolism Reviews · doi:10.1080/03602532.2022.2029475 · Cited by 12 · see citing works

Integrated metabolomics and proteomics analysis of plasma lipid metabolism in Parkinson’s disease

Gątarek, P., & Kałużna‐Czaplińska, J. (2024) · Expert Review of Proteomics · doi:10.1080/14789450.2024.2315193 · Cited by 11 · see citing works

A Proteomics Pipeline for Generating Clinical Grade Biomarker Candidates from Data‐Independent Acquisition Mass Spectrometry (DIA‐MS) Discovery

Fu, Q., Vegesna, M., Sundararaman, N., Damoc, E., Arrey, T. N., Pashkova, A., Mengesha, E., Debbas, P., Joung, S. Y., Li, D., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202409446 · Cited by 11 · see citing works

Proteomics: techniques and applications in neuroscience

Cookson, M. R. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14867 · Cited by 11 · see citing works

Analysis of human brain tissue derived from DBS surgery

Kangas, S. M., Teppo, J., Lahtinen, M., Suoranta, A., Ghimire, B. R., Mattila, P., Uusimaa, J., Varjosalo, M. T., Katisko, J., & Hinttala, R. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00297-y · Cited by 14 · see citing works

Viewpoint on the role of tissue maintenance in ageing: focus on biomarkers of bone, cartilage, muscle, and brain tissue maintenance

van der Spoel, E., van Vliet, N. A., & van Heemst, D. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100964 · Cited by 11 · see citing works

Neurofilament light chain in Alzheimer’s disease

Fuloria, N. K., Sekar, M., Porwal, O., Ansari, M. T., Biswas, A., Narain, K., Biswas, S., Bhatia, S., Dhanalekshmi, U. M., & Fuloria, S. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120580 · Cited by 9 · see citing works

The Potential of ANK1 to Predict Parkinson’s Disease

Xue, J., Li, F.-Z., & Dai, P. (2023) · Genes · doi:10.3390/genes14010226 · Cited by 10 · see citing works

Alzheimer’s disease: a scoping review of biomarker research and development for effective disease diagnosis

Faldu, K. G., & Shah, J. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2104639 · Cited by 9 · see citing works

LC-MS determination of Nicotiana benthamiana host plant proteins in the drug products of recombinant plant-produced pembrolizumab

Daduang, R., Suwanchaikasem, P., Rattanapisit, K., Vitayathikornnasak, S., Srisangsung, T., Bulaon, C. J. I., & Phoolcharoen, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-11541-6 · Cited by 8 · see citing works

Lipidomics and proteomics: An integrative approach for early diagnosis of dementia and Alzheimer’s disease

Tiwari, V., & Shukla, S. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1057068 · Cited by 7 · see citing works

Paradigm shift in biomarker translation: a pipeline to generate clinical grade biomarker candidates from DIA-MS discoveryPreprint

Fu, Q., Vegesna, M., Sundararaman, N., Damoc, E., Arrey, T. N., Pashkova, A., Mengesha, E., Debbas, P., Joung, S. Y., Li, D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.20.586018 · Cited by 6 · see citing works

The role of in silico and in vitro models in Parkinson’s disease: Drug discovery and therapy applications

Himwaba, M., Jarnda, K. V., Dweh, M. T., Liu, X., Xiang, Y., Zou, X., Lv, H., Li, T., Tu, X., & Wang, J. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102953 · Cited by 4 · see citing works

Alzheimer’s disease: where do we stand now and what are the strategic interventions?

González, A., Geywitz, S., & Maccioni, R. B. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1655342 · Cited by 3 · see citing works

A Proteomics Pipeline for Generating Clinical Grade Biomarker Candidates from Data‐Independent Acquisition Mass Spectrometry (DIA‐MS) Discovery

Fu, Q., Vegesna, M., Sundararaman, N., Damoc, E., Arrey, T. N., Pashkova, A., Mengesha, E., Debbas, P., Joung, S. Y., Li, D., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202409446 · Cited by 3 · see citing works

Expanding our understanding of synucleinopathies: proteinopathy, proteinopenia, and lipidopathy

Flores‐León, M., & Outeiro, T. F. (2025) · FEBS Journal · doi:10.1111/febs.70011 · Cited by 3 · see citing works

ProPickML: Advancing Clinical Diagnostics with Automated Peak Picking in Label-Free Targeted Proteomics

Coyle, E., Leclercq, M., Gotti, C., Roux‐Dalvai, F., & Droit, A. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00689 · Cited by 3 · see citing works

Co-extraction for Metabolomics and Proteomics from a Single CSF Sample

Hörmann, P., Barkovits, K., Marcus, K., & Hiller, K. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9706-0_21 · Cited by 3 · see citing works

CSF Sample Preparation for Data-Independent Acquisition

Barkovits, K., Tönges, L., & Marcus, K. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9706-0_4 · Cited by 3 · see citing works

An RNA biomarker panel for the diagnosis of Alzheimer’s disease from whole blood

Paz, S., Robishaw, J. D., & Caputi, M. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01977-x · Cited by 2 · see citing works

“Pandemics-on-a-Chip”: Organ-on-a-Chip Models for Studying Viral Infections

Lima, A. M., Feitor, J. F., Ferreira, V. G., Almeida, M. B., Brazaca, L. C., Cardoso, D. R., & Carrilho, E. (2023) · Springer eBooks · doi:10.1007/978-3-031-27922-5_8 · Cited by 2 · see citing works

Discovering Biomarker Proteins and Peptides for Parkinson’s Disease Prognosis Prediction with Machine Learning and Interpretability MethodsPreprint

Park, H.-M., Kabanga, E. K., Moon, D., Chung, M., Im, J., Kim, Y., Messem, A. V., & Neve, W. D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.18.541380 · Cited by 2 · see citing works

Proteomics As A Valid Tool In Biomarker Discovery For Alzheimer's DiseasePreprint

Magnelli, V. (2024) · Preprints.org · doi:10.20944/preprints202401.1595.v1 · Cited by 1 · see citing works

Mass Spectrometry Imaging for Cellular-level Analysis: Advances and Applications on Medical Research

Yu, Y., Fan, J., Liu, H., & Nie, Z. (2025) · Chemical Research in Chinese Universities · doi:10.1007/s40242-025-4251-5 · Cited by 1 · see citing works

Advancements in biomarker discovery and validation for targeted therapies

Prasanth, T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33877-9.00004-5 · Cited by 1 · see citing works

Aptamers in Drug Design: An Emerging Weapon to Fight a Losing Battle

Jose, J., Thomas, A. M., Mendonsa, D., Al-Sanea, M. M., Uddin, M. S., Parambi, D. G. T., Charyulu, R. N., & Mathew, B. (2019) · Current Drug Targets · doi:10.2174/1389450120666190729121747

Clinical Validation of Neuronal Pentraxin Receptor as a Candidate Biomarker for Alzheimer’s Disease

Lim, B. (2020) · TSpace (University of Toronto)

Developed 3D- Improved Ensemble Deep Neural Network to Detect and Predict PD at the Early Stage

Fiorenza, J. C. E., & Sellam, V. (2023) · International Conference on Research Methodologies in Knowledge Management, Artificial Intelligence and Telecommunication Engineering (RMKMATE) · doi:10.1109/rmkmate59243.2023.10368917

Platelet proteomics: An analytical perspective with reference to tuberculosis

Kannan, E. P., Gopal, J., Deenadayalan, A., & Muthu, M. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.118096

Glycosphingolipids in Dementia: Insights from Mass Spectrometry and Systems Biology Approaches

Sârbu, M., Ică, R., Biricioiu, M. R., Dehelean, L., & Zamfir, A. D. (2025) · Biomedicines · doi:10.3390/biomedicines13122854

Additional file 5 of Analysis of human brain tissue derived from DBS surgery

Kangas, S. M., Teppo, J., Lahtinen, M., Suoranta, A., Ghimire, B. R., Mattila, P., Uusimaa, J., Varjosalo, M. T., Katisko, J., & Hinttala, R. (2022) · Figshare · doi:10.6084/m9.figshare.19596180

APOE, Biomarkers, and Proteogenomics in Alzheimer’s Disease

Pereira, J. D., Tosatti, J. A. G., & Gomes, K. B. (2026) · Springer eBooks · doi:10.1007/978-3-031-52641-1_66-1

APOE, Biomarkers, and Proteogenomics in Alzheimer’s Disease

Pereira, J. D., Tosatti, J. A. G., & Gomes, K. B. (2026) · Springer eBooks · doi:10.1007/978-3-031-96089-5_66

Advances in Multiple Reaction Monitoring (MRM) for Targeted Proteomics in Biomedical Research

Baker, E. N., Geib, T., & Borchers, C. H. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-29437-1_34

Research Progress of Insulin-like Growth Factor-1 in Major Neurodegenerative Diseases

Sun, Y., & Xia, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219696

Development of mass spectrometry-based identification and quantification methods for protein biomarkers in Alzheimer’s and Parkinson’s diseases

Galozzi, S. (2016) · Dokumentenrepositorium der RUB (Ruhr University Bochum)

Biomarkers in Alzheimer’s Disease Analysis by Mass Spectrometry-Based Proteomics

Liu, Y., Qing, H., & Deng, Y. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15057865 · Cited by 50 · see citing works

www.mdpi.com/journal/ijms Review Biomarkers in Alzheimer’s Disease Analysis by Mass Spectrometry-Based Proteomics

Liu, Y., Qing, H., & Deng, Y. (2014)

Neuroproteomics tools in clinical practice

Shevchenko, G., Konzer, A., Musunuri, S., & Bergquist, J. (2015) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2015.01.016 · Cited by 41 · see citing works

P1‐361: The development of mass spectrometry‐based assays for the monitoring of candidate markers of Alzheimer's disease

O'Brien, D. P., Byers, H. L., Kuhn, K., Ward, M. A., Schulz‐Knappe, P., & Lovestone, S. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.943